Satellos Bioscience IncTSX:MSCLView on OTCQB
- LAST PRICE0.4900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.4900
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MSCL |
|---|---|---|
| 01:19 ET | 1500 | 0.49 |
| 03:56 ET | 2000 | 0.49 |
Apr 15, 2024
DJ Satellos Bioscience Price Target Announced at C$1.20/Share by H C Wainwright, from 11:52AM ET on Monday Apr 15, 2024 by Dow Jones
11:52AM ET on Monday Apr 15, 2024 by Dow Jones
Apr 8, 2024
Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, from 7:00AM ET on Monday Apr 08, 2024 by Dow Jones
7:00AM ET on Monday Apr 08, 2024 by Dow Jones
Mar 27, 2024
Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights, from 7:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
7:00AM ET on Wednesday Mar 27, 2024 by Dow JonesPress Release: Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights, from 7:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
7:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Satellos Bioscience Inc | 58.4M | -3.3x | --- |
MustGrow Biologics Corp | 54.9M | -10.4x | --- |
Briacell Therapeutics Corp | 47.3M | -2.6x | --- |
Defence Therapeutics Inc | 69.5M | -4.3x | --- |
Nurexone Biologic Inc | 34.2M | -5.3x | --- |
ZYUS Life Sciences Corp | 70.6M | -3.4x | --- |
Company Information
Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.
Contact Information
- Headquarters
- 200 Bay Street, Suite 2800TORONTO, ON, Canada M5J 2J1
- Phone
- 647-660-1780
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- William Jarosz
- President, Chief Executive Officer, Director
- Andrew Rae
- Chief Financial Officer
- Elizabeth Williams
- Head of Corporate Strategy
- Warren Whitehead
- Independent Director
- Richard Barker
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $55.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 112.8M |
Satellos Bioscience Inc does not pay a dividend. | |
Beta | 1.61 |
EPS | $-0.15 |
Book Value | $0.36 |
P/E Ratio | -3.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
